bluebird bio (NASDAQ:BLUE) Stock Rating Upgraded by ValuEngine

bluebird bio (NASDAQ:BLUE) was upgraded by equities researchers at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Thursday, ValuEngine reports.

BLUE has been the topic of several other reports. William Blair reissued a “buy” rating on shares of bluebird bio in a research note on Friday, May 3rd. BidaskClub raised shares of bluebird bio from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. Wedbush downgraded shares of bluebird bio from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $166.00 to $131.00 in a research note on Wednesday, May 15th. Zacks Investment Research downgraded shares of bluebird bio from a “buy” rating to a “hold” rating in a research note on Tuesday, May 7th. Finally, Gabelli reissued a “buy” rating on shares of bluebird bio in a research note on Friday, July 19th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $157.39.

BLUE traded down $7.87 on Thursday, reaching $120.28. The company had a trading volume of 1,085,377 shares, compared to its average volume of 478,489. The business has a 50 day moving average of $129.64. The stock has a market capitalization of $6.63 billion, a P/E ratio of -11.26 and a beta of 2.25. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.31 and a current ratio of 9.31. bluebird bio has a 52-week low of $87.49 and a 52-week high of $176.55.

bluebird bio (NASDAQ:BLUE) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($3.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.04) by ($0.51). The company had revenue of $13.30 million during the quarter, compared to analysts’ expectations of $13.13 million. bluebird bio had a negative net margin of 1,184.01% and a negative return on equity of 34.01%. The company’s revenue for the quarter was up 68.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.91) earnings per share. On average, equities analysts expect that bluebird bio will post -12.26 EPS for the current fiscal year.

In other news, insider Jeffrey T. Walsh sold 1,400 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $125.44, for a total value of $175,616.00. Following the transaction, the insider now owns 42,321 shares in the company, valued at $5,308,746.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Davidson sold 6,360 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $138.95, for a total transaction of $883,722.00. Following the completion of the transaction, the insider now owns 37,976 shares in the company, valued at approximately $5,276,765.20. The disclosure for this sale can be found here. Insiders sold 18,820 shares of company stock worth $2,493,620 in the last 90 days. Company insiders own 3.00% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Advisor Group Inc. grew its holdings in shares of bluebird bio by 15.5% in the fourth quarter. Advisor Group Inc. now owns 1,256 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 169 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of bluebird bio by 10.8% in the fourth quarter. Legal & General Group Plc now owns 26,564 shares of the biotechnology company’s stock worth $2,636,000 after purchasing an additional 2,581 shares during the last quarter. Peregrine Asset Advisers Inc. bought a new position in shares of bluebird bio in the first quarter worth approximately $2,215,000. MayTech Global Investments LLC grew its holdings in shares of bluebird bio by 445.7% in the first quarter. MayTech Global Investments LLC now owns 30,182 shares of the biotechnology company’s stock worth $4,749,000 after purchasing an additional 24,651 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of bluebird bio by 73.2% in the fourth quarter. Millennium Management LLC now owns 134,987 shares of the biotechnology company’s stock worth $13,391,000 after purchasing an additional 57,055 shares during the last quarter.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.

Further Reading: Why is momentum important to successful trading?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.